Last reviewed · How we verify
AG20012
AG20012 is a small molecule that targets the PI3K/AKT/mTOR pathway.
AG20012 is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | AG20012 |
|---|---|
| Sponsor | Ahn-Gook Pharmaceuticals Co.,Ltd |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AG20012 works by inhibiting the PI3K/AKT/mTOR pathway, which is involved in cell growth and proliferation. This inhibition leads to anti-tumor effects. AG20012 has shown promise in preclinical studies for the treatment of various cancers.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AG20012 CI brief — competitive landscape report
- AG20012 updates RSS · CI watch RSS
- Ahn-Gook Pharmaceuticals Co.,Ltd portfolio CI